inquiry@market.us
+1 718 874 1545 (International)
+91 78878 22626 (Asia)
Search...
All Reports
All Sectors
Who Trust Us
Home ➤ Life Science ➤ Pharmaceuticals ➤ Antiviral Drugs Market
Antiviral Drugs Market by Drug Class (Polymerase Inhibitors, Protease Inhibitors),
By Disease Indication (Hepatitis, Human Immuno Deficiency Virus {HIV}, Influenza
and others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By
Region and Companies - Industry Segment Outlook, Market Assessment,
Competition Scenario, Trends, and Forecast 2023-2032
Published date: Oct 2024
Overview
Report ID: 97163
Table of Contents
Number of Pages: 380
Mention interested
topics/company profiles.
Format:
Major Market Players
Inquiry Before Buying
Request a Free Sample
Enter Name
Enter Email ID
-Select Country-
Quick Navigation
Enter Phone Number
Report Overview
Enter Company Name
The Global Antiviral Drugs Market size is expected to be worth around US$ 71 Billion by 2033,
from US$ 50 Billion in 2023, growing at a CAGR of 3.73% during the forecast period from 2024
to 2033.
Submit
The virus is a part of DNA and RNA bound in a structural protein. They infect human cells and
cause viral infections. Viral infection is considered one of the most common causes of illness
and has a significant impact on the healthcare system across the globe. Antiviral drugs are a
class of medicines mainly used to treat viral infections. Antiviral drugs target various viruses,
such as herpes, influenza, and hepatitis. Broad Spectrum antiviral drugs can be used to treat a
Report ID
range of viruses.
97163
The antiviral agent has a distinct mechanism of action that includes the inhibition of viral DNA
synthesis and thus prevents it from replication. Some antiviral drug acts as protease enzyme
and prevent them from further cell division. The antiviral agent thus restores cells’ normal
function and eliminates the viral infection. Various pharmaceutical industries are developing
Published Date
Oct 2024
Rating
★ ★ ★ ★ ★ (70)
antiviral therapies nationwide to prevent the spread of infectious viral infections.
add_shopping_cart Buy Now
Trusted by more than 17382
organizations globally
Key Takeaways
The antiviral drugs market is projected to be valued at US$ 71.1 billion by 2032.
The market value in 2022 was US$ 49.8 billion.
The estimated market growth rate (CAGR) from 2023 to 2032 is 3.73%.
By Drug Class in 2022, the combination segment generated the highest revenue share.
For Disease Indication, the human immune deficiency virus segment is expected to
register the highest market share.
By Distribution Channel, the hospital pharmacy segment dominates and is expected to
grow at a significant CAGR.
North America had the largest market share of 32% in 2022.
Europe held a revenue share of 20.7% in 2022.
According to the WHO, millions of people globally live with HIV, and many have died
because of it.
The U.S. sees a significant prevalence of infections such as HIV.
Drug Class Analysis
Based on drug class, the global antiviral drugs market is segmented into polymerase
inhibitors, protease inhibitors, reverse transcriptase inhibitors, and combination drugs. The
combination drug segment accounted for the largest market share during the forecast period,
attributable to the significant performance of combination brands such as Genvoya and
Triumeq. Also, USFDA launched novel combination therapies of antiviral medicine for the flu
and is expected to develop the segment’s growth during the forecast period.
The integrase segment is projected to expand in the upcoming years due to the remarkable
performance of drugs. It is a well-tolerated class of antiviral drugs and has higher
effectiveness than other antiviral drugs. These are the key factors for the significant
investment in the R&D of the integrase inhibitors and the anticipated growth of these
segments.
Disease Indication Analysis
Based on disease indication, the antiviral drugs market is divided into hepatitis, human
immunodeficiency virus (HIV), and influenza. The HIV section registers the highest market
share due to the rapid increase in the dominance of HIV infection. Also, developed treatments
for HIV infection and profitable policies for antiviral drug therapy are expected to boost the
growth of this segment.
The high dominance of HIV infection attached to a high treatment rate, the existence of
exclusive drugs, and government initiatives to increase the treatment rate are anticipated to
drive the market at a higher growth rate. For example, the U.S. government announced the
Ending the HIV Epidemic plan to end the HIV epidemic in the country. The initiatives seek to
decrease HIV infection and improve the diagnosis rate in the U.S. However, the presence of
drugs for HIV infection will also fuel the market growth during the forecast period.
The Hepatitis segment held the second-largest revenue share in 2022. The region is expected
to witness a CAGR of 3.73% over the forecast period. The rise in vaccination for Hepatitis A and
B is affecting the growth adversely.
Distribution Channel Analysis
Based on distribution channels, the market is divided into hospital pharmacies, retail
pharmacies, and online pharmacies. The Hospital Pharmacy segment dominates the market
share growth. Government support for viral diseases through establishing government-aided
hospital pharmacies and an improved network of key companies are the major factors
attributable to the expansion of the pharmacy segment.
The online pharmacy section is anticipated to register a relatively significant CAGR during the
forecast period. This is owing to the emerging supply of online pharmacies offering discounts
and their rapid adoption by the masses. The retail pharmacy segment is expected to account
for the increasing number of patients and the availability of OTC and generic medicine for
minor viral infections.
Key Market Segments
By Drug Class
Polymerase Inhibitors
Protease Inhibitors
Integrase Inhibitors
Reverse Transcriptase Inhibitor
Combination Drug
By Disease Indication
Hepatitis
Human Immuno Deficiency Virus(HPV)
Influenza
others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Drivers
Increasing demand for Antiviral Drugs
After an individual coughs or sneezes, fluid in air droplets can spread various infections.
Through the nose or mouth, these fluids enter the body. Antiviral infection can be treated with
several treatment options, including acyclovir and oseltamivir. In a similar vein, these
medications aid in spreading the flu virus throughout the body, further advancing the market.
As a result, the market’s expansion is fueled mainly by an increasing number of people taking
antiviral medications. However, the strong presence of generic pharmaceutical manufacturing
companies in India and other countries increasing the geriatric population in the region are
some of the key factors driving the market growth. Similarly, Product approval is another factor
driving the growth of the market.
Increasing Prevalence of HIV and Influenza to Fuel Growth of Market
HIV is developing as the most common form of viral infection worldwide. Boosted observation
for HIV by using demographic and biological data has developed the diagnosis rate of the
disease. According to WHO, millions of people are living with HIV around the globe, and a
maximum was died because of this disease. Hence the increasing problem of this infection is
enhancing the demand for targeted and specific treatment propelling the antiviral agents
market growth.
Restraints
Challenges and Limitations in the Antiviral Drugs Market
Limited Options for Broad-Spectrum, cost-effective, and accessible antiviral drugs is a
significant factor restraining the market revenue growth. Developing safe, effective, and
targeted antivirals from the ground up is time-consuming, which is anticipated to limit the
market revenue growth. Direct-acting antivirals, broad-spectrum antiviral drugs that can be
quickly deployed on a massive scale to prevent viral spread while effective vaccines are being
developed, are essential in light of the possibility of future viral pandemics.
Currently, most approved antivirals on the market are host-directed antivirals, which are a
significant obstacle to the enhancement and determination of drug-resistant mutations. This
is expected to limit market revenue growth. During the forecast period, market revenue growth
may be determined by the need for significant investments in R&D activities for the
introduction of novel and efficient antiviral medications. The market revenue growth is also
expected to be hampered by increased infection prevention measures and vaccine
availability awareness.
Opportunity
Growing opportunity for several organization
The market is expected to expand due to the projected commercialization of several new
medicines for viral infections and increasing approval. For instance, a supplementary New
Drug Application for Roche’s Xofluza to treat influenza patients aged 12 and older was
approved by the U.S. FDA.
In addition, the major market players have introduced several novel medicines to treat various
viral infections over the past two to three years. For treating viral infections, Gilead Sciences,
Inc. has developed, for instance, Biktarvy, Symtuza, and Veklury. As a result, this factor boosts
market expansion.
Increasing strategic collaboration with a different organization
It is anticipated that in the coming years, a large number of novel drugs will be developed due
to increasing collaborations for developing and manufacturing various antiviral medications.
To reduce the burden of viral infection treatment, major market players are working together
to research and develop new therapies.
For instance, to increase the supply of remdesivir, Gilead Sciences, Inc. has signed licensing
agreements with leading pharmaceutical companies. These companies include Hetero Labs
Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Mylan, and others.
Regional Analysis
North America region accounted significant share of the global antiviral drugs market
North America accounted for a significant antiviral drugs market share of revenue of 32%. This
is attributable to the presence of key pharmaceuticals in the U.S., increasing the dominance of
infections such as HIV in the country, and the green signal by the US FDA for the launch of
effective therapies in North America. Europe is expected to witness remarkable growth in the
upcoming countries due to favorable policies for antiviral drugs and key players involved in
the antiviral medication of R&D.
Moreover, Asia-Pacific is expected to reflect a relatively highest CAGR during the forecast
period. Government participation in managing viral infection and increasing penetration of
companies are anticipated to boost the medicine market.
Also, efforts made by public players to improve awareness of critical viral diseases such as HIV
in the Middle & East Africa are projected to augment revenue generation in the upcoming
years. The market is projected to flourish in Europe due to new product launches and active
government support.
Key Regions
North America
The US
Canada
Mexico
Western Europe
Germany
France
The UK
Spain
Italy
Portugal
Ireland
Austria
Switzerland
Benelux
Nordic
Rest of Western Europe
Eastern Europe
Russia
Poland
The Czech Republic
Greece
Rest of Eastern Europe
APAC
China
Japan
South Korea
India
Australia & New Zealand
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Rest of APAC
Latin America
Brazil
Colombia
Chile
Argentina
Costa Rica
Rest of Latin America
Middle East & Africa
Algeria
Egypt
Israel
Kuwait
Nigeria
Saudi Arabia
South Africa
Turkey
United Arab Emirates
Rest of MEA
Key Players Analysis
Many available pharmaceutical companies are involved in the manufacturing and distributing
of antiviral drugs and making the global market highly competitive. Moreover, Gilead Sciences
and GlaxoSmithKline Plc. Held a significant market share during the forecast period.
Various prominent major companies in the antiviral drug industry include Gilead Sciences,
GlaxoSmithKline Plc., Abbive Inc., Merck & Co, Inc., Janssen Pharmaceutical, Novartis AG, Mylan
NV, Bristol-Meyrs Squibb Company, and others. These industry players are adopting several
growth strategies to attain a sustainable advantage.
Market Key Players
Gilead Sciences Inc.
AbbVie, Inc.
GlaxoSmithKline
Merck& C.O., Inc.
Jannssen Pharmaceuticals, Inc.
Bristol- Meyrs Squibb Company
Mylan N. V.
Novartis AG
AstraZeneca
Pfizer Inc.
Cipla Inc.
Johnson & Johnson Services, Inc.
Aurobindo Pharma
Merck MRK
Reddy Laboratories Limited
Hoffmann-La Roche Ltd.
Altesa Biosciences Inc.
Other Key Players
Recent Development
In March 2024: Gilead Sciences completed the acquisition of CymaBay Therapeutics for
approximately $4.3 billion. This acquisition was finalized after a tender offer process
initiated in February 2024, where Gilead purchased all outstanding shares of CymaBay.
The merger has integrated CymaBay as a wholly owned subsidiary of Gilead, enhancing
its liver disease portfolio, particularly with CymaBay’s investigational product candidate,
seladelpar.
In January 2024: GSK announced plans to introduce at least 12 new drugs from 2025,
focusing on infectious diseases, HIV, respiratory conditions, and oncology. This strategic
move is supported by a robust pipeline and recent successful financial outcomes,
including a 3% growth in sales to £30.33 billion for Fiscal Year 2023. GSK expects this
pipeline to drive sales and profit growth in the coming years.
In January 2023: AbbVie and Anima Biotech announced a collaboration focusing on the
development of mRNA biology modulators, which could include antiviral targets. Anima
Biotech will receive an upfront payment of $42M with the potential to earn up to $540M in
additional milestone payments across the collaboration’s various stages. This
agreement showcases AbbVie’s investment in cutting-edge mRNA technology to
potentially enhance antiviral drug development.
Report Scope
Report Features
Description
Market Value (2022)
US$ 49.8 Bn
Forecast Revenue
US$ 71.1 Bn
(2032)
CAGR (2023-2032)
3.7%
Base Year for Estimation
2022
Historic Period
2016-2022
Forecast Period
2023-2032
Report Coverage
Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive
Landscape, Recent Developments
Segments Covered
By Drug Class-Polymerase Inhibitor, Protease Inhibitor, Integrase
Inhibitor, Reverse Transcriptase Inhibitor, and Combination Drugs; By
Disease Indication- Hepatitis, Human Immuno Deficiency Virus,
Influenza, and Others; By Distribution Channel- Hospital Pharmacy,
Retail Pharmacy, and Online Pharmacy
Regional Analysis
North America – The US, Canada, & Mexico; Western Europe –
Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria,
Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe
– Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe;
APAC – China, Japan, South Korea, India, Australia & New Zealand,
Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest
of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica,
& Rest of Latin America; the Middle East & Africa – Algeria, Egypt, Israel,
Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab
Emirates, & Rest of MEA
Competitive Landscape
Gilead Sciences Inc., AbbVie, Inc., GlaxoSmithKline, Merck&Co, Inc.
Jannssen Pharmaceutical, Inc., Pfizer Inc., Cipla Inc. Aurobindo
Pharma, and Other Key Players
Customization Scope
Customization for segments, region/country-level will be provided.
Moreover, additional customization can be done based on the
requirements.
Purchase Options
We have three licenses to opt for: Single User License, Multi-User
License (Up to 5 Users), Corporate Use License (Unlimited User and
Printable PDF)
Antiviral Drugs Market
Published date: Oct 2024
add_shopping_cart Buy Now
get_app Download Sample
Related Reports
Drug Repurposing Market
Human Antihistamine Drug Market
Ursodeoxycholic Acid Drug Product Market
Vulvodynia Treatment Drug Market
Sinus Therapeutic Drug Market
Bacterial Vaginosis Rx Drug Market
Our Clients
SINGLE USER
MULTI USER
$6,000
$8,000
CORPORATE USER
$10,000
$3,999
$5,999
$6,999
USD / PER UNIT
USD / PER UNIT
USD / PER UNIT
SAVE 24%
SAVE 28%
SAVE 32%
No
up to 10 hrs work
up to 30 hrs work
1 User
2-5 User
Unlimited
up to 20 hrs
up to 40 hrs
up to 50 hrs
Up to 20% off on next purchase
Up to 25% off on next purchase
Up to 30% off on next purchase
Buy Now ($ 3,999)
Buy Now ($ 5,999)
Buy Now ($ 6,999)
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization
Accessibility
Analyst Support
Benefit
Lexington Avenue, Suite
location_on 420
300 New York City, NY 10170,
United States
phone +1 718 874 1545 (International)
phone +91 78878 22626 (Asia)
email inquiry@market.us
Find Help
Explore
Contact Us
About Us
How to Order
All Reports
Legal
Privacy Policy
Refund Policy
Frequently Asked Questions
Terms and Conditions
© 2025 Market.Us. All Rights Reserved.
All Sectors
Infographics
Statistics and Facts
Companies
Secured Payment Options